COMMUNIQUÉ DE PRESSE publié le 19/08/2024 à 13:30, il y a 2 mois 22 jours MIRA Pharmaceuticals Showcases Significant Progress and Announces Final Phase of Regulatory Work as It Prepares for IND Submission by Year-End MIRA Pharmaceuticals, a leading pre-clinical-stage company, provides an update on its achievements and scientific advancements, nearing a milestone: IND application submission for Ketamir-2 and regulatory progress for MIRA-55 IND Application Scientific Advancements MIRA Pharmaceuticals Regulatory Progress Pre-clinical-stage
BRÈVE publiée le 12/08/2024 à 14:05, il y a 2 mois 29 jours MIRA Pharmaceuticals Unveils Promising Metabolite Nor-Ketamir-2 Neurological Treatments Preclinical Data Bioavailability Ketamir-2 Nor-Ketamir-2
BRÈVE publiée le 12/08/2024 à 14:05, il y a 2 mois 29 jours MIRA Pharmaceuticals dévoile un métabolite prometteur, le Nor-Ketamir-2 Biodisponibilité Ketamir-2 Nor-Ketamir-2 Traitements Neurologiques Données Précliniques
COMMUNIQUÉ DE PRESSE publié le 12/08/2024 à 14:00, il y a 2 mois 29 jours MIRA Pharmaceuticals Unveils Ketamir-2's Principal Metabolite: Nor-Ketamir - a Longer-Acting, Brain Penetrating and Selective Compound Acting on the NMDA PCP Receptor MIRA Pharmaceuticals unveils new preclinical data on innovative drug candidate Ketamir-2's metabolite Nor-Ketamir-2, showcasing enhanced bioavailability and formulation for advanced at-home neurological treatments Neurological Treatments Preclinical Data Bioavailability MIRA Pharmaceuticals Ketamir-2
BRÈVE publiée le 25/07/2024 à 13:05, il y a 3 mois 16 jours MIRA Pharmaceuticals dévoile des données de liaison sélectives NMDA pour Ketamir-2 Approbation De La FDA Analogue De Kétamine Récepteur NMDA Effets Secondaires Toxicologie
BRÈVE publiée le 25/07/2024 à 13:05, il y a 3 mois 16 jours MIRA Pharmaceuticals Unveils Selective NMDA Binding Data for Ketamir-2 FDA Approval Ketamine Analog NMDA Receptor Side Effects Toxicology
COMMUNIQUÉ DE PRESSE publié le 25/07/2024 à 13:00, il y a 3 mois 16 jours MIRA Pharmaceuticals Announces Positive Discovery of Ketamir-2’s Selective NMDA Binding Mechanism of Action MIRA Pharmaceuticals announced positive preclinical data for novel ketamine analog Ketamir-2, showing selective NMDA inhibition and enhanced safety profile, advancing towards potential IND submission Preclinical Data Neurological Disorders MIRA Pharmaceuticals Ketamir-2 IND Submission
BRÈVE publiée le 22/07/2024 à 14:05, il y a 3 mois 19 jours MIRA Pharmaceuticals annonce des résultats précliniques prometteurs pour Ketamir-2 Troubles Neurologiques Résultats Précliniques Ketamir-2 Pénétration Cérébrale Demande FDA
BRÈVE publiée le 22/07/2024 à 14:05, il y a 3 mois 19 jours MIRA Pharmaceuticals Announces Promising Preclinical Results for Ketamir-2 Neurological Disorders Preclinical Results Ketamir-2 Brain Penetration FDA Application
COMMUNIQUÉ DE PRESSE publié le 22/07/2024 à 14:00, il y a 3 mois 19 jours MIRA Pharmaceuticals Reveals Preclinical Success: Ketamir-2 Optimized for Brain Delivery, Avoiding Ketamine's Drug Resistance MIRA Pharmaceuticals reveals new promising preclinical data for Ketamir-2, a novel oral ketamine analog, indicating potential advantages for treating neurological and neuropsychiatric disorders Preclinical Study Neurological Disorders MIRA Pharmaceuticals Neuropsychiatric Disorders Ketamir-2
Publié le 08/11/2024 à 18:00, il y a 2 jours 2 heures Covivio - Informations relatives au nombre total de droits de vote et d’actions composant le capital social
Publié le 08/11/2024 à 18:00, il y a 2 jours 2 heures Covivio - Information on total number of voting rights and share capital
Publié le 08/11/2024 à 17:52, il y a 2 jours 2 heures Total number of voting rights and shares making up the share capital at October 31, 2024
Publié le 08/11/2024 à 17:45, il y a 2 jours 2 heures CHARGEURS - Voting rights monthly statement as of October 31st, 2024
Publié le 10/11/2024 à 02:00, il y a 18 heures 10 minutes Spey Resources Corp. enters into Share Exchange Agreement with Antimony Assets and announces Name Change
Publié le 09/11/2024 à 16:30, il y a 1 jour 3 heures New to the Street Premieres Episode 611 on Bloomberg Television Tonight at 6:30 PM EST, Featuring Zapp Electric Vehicles, OriginClea and PillSafe
Publié le 09/11/2024 à 04:00, il y a 1 jour 16 heures Freedom Holding Corp. Reports Second Quarter Fiscal Year 2025 Financial Results
Publié le 08/11/2024 à 23:05, il y a 1 jour 21 heures Murchison Minerals Announces Non-Brokered Private Placement
Publié le 10/11/2024 à 13:20, il y a 6 heures 49 minutes EQS-Adhoc: Delivery Hero SE decides on the intended IPO of Talabat Holding plc and plans to use proceeds for general corporate purposes and capital structure optimisation
Publié le 08/11/2024 à 18:35, il y a 2 jours 1 heure Fuller, Smith & Turner PLC: Transaction in own shares
Publié le 08/11/2024 à 18:20, il y a 2 jours 1 heure ENCAVIS achieves results in the first three quarters of 2024 below the figures for the same period of the previous year due to unforeseeable events and adjusts guidance for the current financial year
Publié le 08/11/2024 à 18:02, il y a 2 jours 2 heures Funding Circle Plc: POS-Transaction in Own Shares